{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=42", "query": { "intervention": "Combination Agent", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 5568, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:18:53.895Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05025085", "title": "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "AGEN1777", "type": "DRUG" }, { "name": "a PD-1 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 11, "location_summary": "Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025085" }, { "nct_id": "NCT07044297", "title": "A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus (HIV)", "HIV Pre-Exposure Prophylaxis" ], "interventions": [ { "name": "MK-8527", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Placebo to MK-8527", "type": "DRUG" }, { "name": "Placebo to FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 4390, "start_date": "2025-07-31", "completion_date": "2027-07-22", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044297" }, { "nct_id": "NCT04566133", "title": "Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Biliary Cancer", "Biliary Tract Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-02-15", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566133" }, { "nct_id": "NCT01967758", "title": "Phase I Study of Safety and Immunogenicity of ADU-623", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytic Tumors", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Brain Tumor" ], "interventions": [ { "name": "Cohort 1", "type": "BIOLOGICAL" }, { "name": "Cohort 2", "type": "BIOLOGICAL" }, { "name": "Cohort 3", "type": "BIOLOGICAL" }, { "name": "Antibiotics", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2014-01-08", "completion_date": "2018-08-15", "has_results": false, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967758" }, { "nct_id": "NCT04008043", "title": "Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Oral Surgery" ], "interventions": [ { "name": "Vicodin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 0, "start_date": "2020-02", "completion_date": "2021-05", "has_results": false, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008043" }, { "nct_id": "NCT01108510", "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2010-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01108510" }, { "nct_id": "NCT03532217", "title": "Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "TriGrid Delivery System", "type": "DEVICE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Peripheral blood", "type": "PROCEDURE" }, { "name": "Fecal samples", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2018-09-14", "completion_date": "2022-07-25", "has_results": false, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532217" }, { "nct_id": "NCT03022318", "title": "Carbidopa-levodopa in Neovascular AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "carbidopa-levodopa 25-100 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Snyder, Robert W., M.D., Ph.D., P.C.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 20, "start_date": "2017-05-02", "completion_date": "2020-05-04", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03022318" }, { "nct_id": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Ovarian Carcinoma-Enrollment Completed", "Colorectal Cancer (CRC)-Enrollment Completed", "Renal Cell Carcinoma (RCC) (Phase ll Only)", "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed" ], "interventions": [ { "name": "Combination of varlilumab and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-01", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335918" }, { "nct_id": "NCT04406740", "title": "Clinical Evaluation of a Novel Neuromuscular Blockade Monitoring System", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anesthesia" ], "interventions": [ { "name": "TwitchView EMG Unit", "type": "DEVICE" }, { "name": "Novel QTOF Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-06-18", "completion_date": "2021-06-01", "has_results": false, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-11-15T18:18:53.895Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04406740" } ] }